(0.17%) 5 140.00 points
(0.12%) 38 488 points
(0.24%) 17 888 points
(-0.23%) $83.66
(1.61%) $1.954
(0.14%) $2 350.60
(0.65%) $27.72
(1.66%) $937.45
(-0.16%) $0.933
(-0.29%) $10.99
(-0.32%) $0.798
(1.18%) $92.96
Live Chart Being Loaded With Signals
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders...
Stats | |
---|---|
Šios dienos apimtis | 5 194.00 |
Vidutinė apimtis | 24 942.00 |
Rinkos kapitalizacija | 3.63M |
EPS | $0 ( 2024-03-27 ) |
Kita pelno data | ( $0 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.240 |
ATR14 | $0.0710 (2.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-29 | Singh Vanila | Buy | 25 000 | Stock Option (right to buy) |
2024-01-29 | Shah Vinay | Buy | 112 000 | Stock Option (right to buy) |
2024-01-29 | Jambulingam Thani | Buy | 25 000 | Stock Option (right to buy) |
2024-01-29 | Mathias Sheila | Buy | 112 000 | Stock Option (right to buy) |
2024-01-29 | Dubin Michael F | Buy | 25 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
75.05 |
Last 71 transactions |
Buy: 2 396 200 | Sell: 387 701 |
Virpax Pharmaceuticals, Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
XBIO | 0.884 |
TRIP | 0.875 |
LTRPA | 0.868 |
SCWX | 0.852 |
SVAC | 0.851 |
GOODM | 0.845 |
MIND | 0.832 |
YTEN | 0.832 |
PRPO | 0.829 |
NVFY | 0.824 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
LWAC | -0.895 |
SRAC | -0.874 |
AFINO | -0.852 |
NETE | -0.845 |
RAVN | -0.839 |
AMRB | -0.82 |
LMRKN | -0.82 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Virpax Pharmaceuticals, Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-12.97 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-12.97 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-18.32 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.67 |
Financial Reports:
No articles found.
Virpax Pharmaceuticals,
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.